Supernus Pharmaceuticals
SUPN
243 hedge funds and large institutions have $1.37B invested in Supernus Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 87 increasing their positions, 91 reducing their positions, and 49 closing their positions.
23% more call options, than puts
Call options by funds: $14.1M | Put options by funds: $11.5M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 91
4.65% less ownership
Funds ownership: 100.97% → 96.32% (-4.6%)
11% less funds holding
Funds holding: 272 → 243 (-29)
20% less capital invested
Capital invested by funds: $1.71B → $1.37B (-$347M)
55% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$19.9M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$19.3M |
| 3 |
ACB
Aristotle Capital Boston
Boston,
Massachusetts
|
+$19M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$9.6M |
| 5 |
MCM
Matarin Capital Management
New York
|
+$9.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$28.4M |
| 2 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$27.1M |
| 3 |
PIM
Provident Investment Management
Novi,
Michigan
|
-$24M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$19.3M |
| 5 |
RIM
Ranger Investment Management
Dallas,
Texas
|
-$15.5M |
SUPN Hedge Fund Activity: Q3 2019 in Review
243 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2019, worth a combined $1.37B — down 20% from $1.71B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of SUPN and 22 opened new positions — a net loss of 27 holders — while 91 trimmed existing stakes and 87 added.
The largest buyer was Fuller & Thaler Asset Management, adding an estimated $19.9M. The largest seller was Champlain Investment Partners, cutting an estimated $28.4M.
- 243 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2019, down from 272 in Q2 2019.
- Funds reported $1.37B of Supernus Pharmaceuticals stock for Q3 2019, down 20% quarter-over-quarter.
- 22 funds opened new Supernus Pharmaceuticals positions in Q3 2019 and 49 closed out, a net change of -27 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2019 was Fuller & Thaler Asset Management, an estimated $19.9M added.
- The largest Supernus Pharmaceuticals seller in Q3 2019 was Champlain Investment Partners, an estimated $28.4M sold.
Based on aggregated 13F filings for Q3 2019.